A study cited that prostasin, a trypsin-like serine peptidase produced in epithelial cells, may be a viable target for the treatment or repression of some ovarian cancers by altering the CASP/PAK2-p34 pathway [67]. This evidence concerns the gene PAK2 and ovarian carcinoma.